NCT05766488
Assessing Continuous Glucose Monitor Use in Underserved Primary Care Patients
Enrolling by Invitation
NAAges 19+InterventionalTreatmentUniversity of NebraskaInvestigator-initiated
~50 participants
Updated 2025-09-30 on ClinicalTrials.gov
What's tested:Continuous Glucose Monitor (CGM)Self-monitoring Blood Glucose (SMBG)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glycemic Control (Hemoglobin A1c)
Measured over Baseline, 3 months, and 6 months.
Conditions
Where it's being run
1 sites across 1 statesNebraska1
Study leadership
- Drew C Prescott, PharmD · PRINCIPAL_INVESTIGATOR · University of Nebraska
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Type 2 diabetes
A1c \>9% at recruitment
On/initiating insulin or on two or more diabetes medications
Exclusion
Current use of an insulin pump
On dialysis
Pregnant
Implanted medical device (e.g., pace-maker, defibrillator)
Intellectual or physical disabilities that may interfere with ability to properly use the Continuous Glucose Monitor (CGM)
Able to read English
What this trial measures
- Glycemic Control (Hemoglobin A1c)Baseline, 3 months, and 6 months.
Glycemic control will be assessed by measuring hemoglobin A1c at baseline, 3 months, and 6 months. Values will be evaluated as a continuous variable and categorized as \<7.0% vs \>7.0% to \<9.0% and \>9.0%. Comparisons of the proportions of participants achieving a minimum of 1 point drop in hemoglobin A1c will be made between study arms.